Home Page

hyperCORE International has welcomed Apex Trials to its super network of clinical trial sites. Apex Trials is based in a state-of-the-art, 17,000 sq ft facility in Southwestern Ontario, Canada, and conducts studies in both the pharmaceutical and nutraceutical industries. The partnership will bring hyperCORE new and expanded capabilities in health product development, including dietary supplements, medical foods and devices, biologics, and other pharmaceuticals

GUELPH, Ontario, Jan. 30, 2023 /PRNewswire-PRWeb/ -- hyperCORE International is kicking off 2023 in an exciting manner by welcoming Apex Trials to its super network of clinical trial sites. This new addition to their family of alliance partners allows the organization to continue expanding their reach and capabilities across the clinical research arena.

Headquartered in a state-of-the-art, 17,000 square foot facility in Southwestern Ontario, Canada, the newly named Apex Trials is a premium clinical trial site, conducting studies in both the pharmaceutical and nutraceutical industries. Under the leadership of Primary Investigator Dr. Anthony Bier, their primary areas of clinical trial focus are Phase I / Pharmacokinetic studies through Phase IV Studies for both Pharmaceutical and Nutraceuticals for cardiovascular disease, hypertension, dyslipidemia, diabetes, irritable bowel syndrome, and weight management.

"The Apex Trials team at Nutrasource has been working diligently to prepare and scale our site for pharmaceutical studies. Entrance into the prestigious hyperCORE site solutions family, one of the industry's best, is a validation and affirmation of this strategic focus. We are thrilled to join hyperCORE," said William Rowe, President and CEO of Nutrasource.

Apex Trials is part of global CRO and leading nutraceutical nutraceutical and pharmaceutical life sciences company Nutrasource. Nutrasource brings together the strategy, expertise and services required to help clients commercialize health and wellness products with strong science and regulatory confidence. Their unique offering of clinical trial management full suite clinical trial services, strategic and global regulatory consulting services, along with a state-of-the-art clinical trial site has been developed with one goal in mind – success in the global marketplace.

The partnership with Apex Clinical Trials brings hyperCORE new and expanded capabilities in health product development ranging from dietary supplements, medical foods and devices, biologics, and other pharmaceuticals. This greatly adds to hyperCORE's vast array of services and further strengthens its position as a premier provider of clinical trial services.

"It's been a pleasure to work with Apex Trials over the years, and even more exciting that they are joining hyperCORE. This will help strengthen hyperCORE's Canadian approach on pivotal clinical trials and bring expertise on nutraceutical clinical research," said Mark Lacy, Founder and CEO of Benchmark Research and Chair of hyperCORE's exective board.

At the current time, hyperCORE International is comprised of over 100 clinical trial sites across North and South America and offers streamlined efficiencies such as single budget and contracts, and shared platforms for rapid scalability; the network also offers unparalleled access to diverse populations and depth of expertise across vaccine, metabolic disorders, dermatology, and many additional therapeutic areas.

About hyperCORE International:

Formed in 2019, hyperCORE International is a super network of highly experienced and awarded clinical research site/network companies. It is an industry leader, providing Phase I-IV clinical trial services with more than 100 active research sites on two continents and five countries. Its member companies have more than 100 years of combined experience and completed more than 7,000 studies helping to evaluate thousands of new drugs and treatments in more than 140,000 randomized patients. Each member operates as an independent company but integrates common functions to streamline business and clinical operations through harmonization and sharing of best practices.

hyperCORE International is committed to the highest standard of research excellence with subject safety, data integrity, rapid study startup, diversity in enrollment, and outstanding subject retention as top priorities. Its members have won numerous awards for performance, quality, and innovation.

Learn more at hypercoreinternational.com.

Media Contact

Michael Casey, hyperCORE International, 1 919-302-4090, mcasey@hypercoreinternational.com

SOURCE hyperCORE International